Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 1/20 | 0.50 |
| ▸ | ENPP3 | O14638 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.45 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.45 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.44 |
| ▸ | FYN | P06241 | 1/20 | 0.44 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.44 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 2/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.42 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.42 |
| ▸ | FNTA | P49354 | 1/20 | 0.41 |
| ▸ | FNTB | P49356 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6561397 | 0.84 | ACHE (0.61) | PGRENPP3ACHEFYNCLK4 | |
| SCHEMBL6300449 | 0.83 | ESR2 (0.44) | PGRENPP3MAPTPARP10PARP11 | |
| SCHEMBL27645045 | 0.83 | NR3C2 (0.44) | PGRPARP10PARP11NR3C2ACHE | |
| SCHEMBL18797759 | 0.82 | ACHE (0.65) | PGRENPP3ACHEHSD17B1HSD17B2 | |
| SCHEMBL30645462 | 0.82 | ENPP3 (0.53) | PGRENPP3MAPTPARP10PARP11 | |
| SCHEMBL9876129 | 0.81 | CNR2 (0.51) | PGRENPP3MAPTACHEPDK2 | |
| SCHEMBL7776584 | 0.80 | ESR2 (0.53) | PGRENPP3MAPTPARP10PARP11 | |
| SCHEMBL23003863 | 0.80 | ACHE (0.55) | PGRENPP3ACHEFYNCLK4 | |
| SCHEMBL20689786 | 0.80 | TSHR (0.55) | PGRENPP3MAPTACHEPDK2 | |
| SCHEMBL5545442 | 0.80 | ACHE (0.55) | PGRENPP3ACHEFYNCLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11796534-B2 | Methods for assessing cell surface glycosylation | JUNO THERAPEUTICS, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-20210255173-A1 | METHODS FOR ASSESSING CELL SURFACE GLYCOSYLATION | JUNO THERAPEUTICS, INC. (US) | 2021-08-19 | — | — | US | disclosed |
| US-10416166-B2 | Rapid fluorescence tagging of glycans and other biomolecules with enhanced MS signals | WATERS TECHNOLOGIES CORPORATION (US) | 2019-09-17 | — | — | US | disclosed |
| US-20140242709-A1 | RAPID FLUORESCENCE TAGGING OF GLYCANS AND OTHER BIOMOLECULES WITH ENHANCED MS SIGNALS | WATERS TECHNOLOGIES CORPORATION (US) | 2014-08-28 | — | — | US | disclosed |
| US-8475924-B2 | Compositions and methods for creating electronic circuitry | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2013-07-02 | — | — | US | disclosed |
| US-8449949-B2 | Compositions and methods for creating electronic circuitry | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2013-05-28 | — | — | US | disclosed |
| EP-2165582-B1 | COMPOSITIONS AND METHODS FOR CREATING ELECTRONIC CIRCUITRY | DU PONT (US) | 2012-08-22 | — | — | EP | disclosed |
| US-20100181284-A1 | METHOD OF OBTAINING ELECTRONIC CIRCUITRY FEATURES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-07-22 | — | — | US | disclosed |
| US-20090226711-A1 | Biaxially Oriented Nanocomposite Film, Method of Manufacture, and Articles Thereof | GENERAL ELECTRIC COMPANY (US) | 2009-09-10 | — | — | US | disclosed |
| US-20090017309-A1 | COMPOSITIONS AND METHODS FOR CREATING ELECTRONIC CIRCUITRY | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10416166-B2 | Rapid fluorescence tagging of glycans and other biomolecules with enhanced MS signals | FUT5, FUT6, CSGALNACT1 | PGR 4665/4885ENPP3 1921/4885MAPT 2357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.